NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene AmplificationHER2 Positive Gastric CancerSalivary Gland CancerSalivary Gland TumorSalivary Gland CarcinomaSalivary Gland NeoplasmsLung CancerColo-rectal CancerRare DiseasesSolid TumorRecurrent Gastric CancerRecurrent Colon CancerRecurrent Breast CancerHead and Neck CancerHead and Neck CarcinomaBladder CancerCervical CancerLiver CancerBile Duct CancerUrologic CancerPancreatic CancerProstate CancerRecurrent Prostate CancerRectal CancerRecurrent Ovarian CarcinomaRecurrent Renal Cell CancerRectal Cancer Stage IIRectal Cancer Stage IRectal Cancer Stage IIISkin CancerMouth CancerLip Cancer Stage ITongue CancerBreast Neoplasm Malignant PrimaryLarynx CancerTonsil CancerPalate CancerMucoepidermoid CarcinomaPrimary Peritoneal CarcinomaMucinous Adenocarcinoma GastricMucinous Breast Cancer RecurrentCholangiocarcinoma

Interventions

DRUG

A166

A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Trial Locations (10)

11042

Clinical Research Alliance, Inc., Lake Success

22031

Virginia Cancer Specialist, Fairfax

34232

Florida Cancer Specialists & Research Institute, Sarasota

48201

Karmanos Cancer Institute, Detroit

73104

Stephenson Cancer Center, Oklahoma City

75230

Mary Crowley Cancer Research Centers - Medical City, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, LLC (START), San Antonio

97213

Providence Cancer Institute, Portland

02215

Beth Israel Deaconess Medical Center Cancer Center, Boston